ALB and breast cancer: Recently, a novel systemic inflammation score system (SIS) based on the lymphocyte to monocyte ratio (LMR) and albumin (Alb) was found to be associated with the outcome of patients with different solid tumors [11–14], including breast cancer patients [15].